Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D00QMQ
|
||||
Former ID |
DNC013675
|
||||
Drug Name |
D-220
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C22H27Cl2N5S
|
||||
Canonical SMILES |
C#CCN(CCN1CCN(CC1)C2=C(C(=CC=C2)Cl)Cl)C3CCC4=C(C3)SC(=N<br />4)N
|
||||
InChI |
1S/C22H27Cl2N5S/c1-2-8-28(16-6-7-18-20(15-16)30-22(25)26-18)12-9-27-10-13-29(14-11-27)19-5-3-4-17(23)21(19)24/h1,3-5,16H,6-15H2,(H2,25,26)
|
||||
InChIKey |
AWFHSDHVMOYPMI-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | D(3) dopamine receptor | Target Info | Inhibitor | [1] | |
D(2) dopamine receptor | Target Info | Inhibitor | [1] | ||
KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
Dopaminergic synapsehsa04015:Rap1 signaling pathway | |||||
cAMP signaling pathway | |||||
Gap junction | |||||
Dopaminergic synapse | |||||
Parkinson's disease | |||||
Cocaine addiction | |||||
Alcoholism | |||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
Dopamine receptor mediated signaling pathway | |||||
Nicotine pharmacodynamics pathway | |||||
Reactome | Dopamine receptors | ||||
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors | |||||
G alpha (i) signalling events | |||||
WikiPathways | Monoamine GPCRs | ||||
GPCRs, Class A Rhodopsin-like | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
Nicotine Activity on Dopaminergic Neurons | |||||
GPCRs, OtherWP666:Hypothetical Network for Drug Addiction | |||||
Genes and (Common) Pathways Underlying Drug Addiction | |||||
References | |||||
REF 1 | J Med Chem. 2008 May 22;51(10):3005-19. Epub 2008 Apr 12.Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.